LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Study Explains How Drug Carriers Interact with Immune System

By LabMedica International staff writers
Posted on 20 Apr 2017
Image: Circulating white blood cells, commonly referred to as leukocytes (large yellow clusters), can be seen lining an inflamed vessel wall along with leukosomes (small yellow speckles). Leukosomes, designed to mimic white blood cells, go unnoticed as they accumulate at the inflamed vessel (purple background), allowing them to concentrate their therapeutic payload at the target site (Photo courtesy of Houston Methodist Hospital).
Image: Circulating white blood cells, commonly referred to as leukocytes (large yellow clusters), can be seen lining an inflamed vessel wall along with leukosomes (small yellow speckles). Leukosomes, designed to mimic white blood cells, go unnoticed as they accumulate at the inflamed vessel (purple background), allowing them to concentrate their therapeutic payload at the target site (Photo courtesy of Houston Methodist Hospital).
Researchers seeking to develop nanoparticle-based drug delivery systems have determined how a specialized class of nanoparticles called leukosomes avoids immune system response in a mouse model system.

Understanding interactions occurring at the interface between nanoparticles and biological components is an urgent challenge in nanomedicine due to their effect on the biological fate of the nanoparticles. After the systemic injection of nanoparticles, a protein corona constructed by blood components surrounds the carrier’s surface and modulates its pharmacokinetics and biodistribution. Immune cells such as leukocytes freely circulate in blood vessels, recognize inflammation, and accumulate in inflamed tissues. They do so by using special receptors and ligands on their surface.

Investigators at Houston Methodist Hospital had previously purified leukocytes from a patient and then integrated their special ligands and receptors into the surface of liposome-like particles, which they called leukosomes. Using the body’s own materials, they built a drug delivery system camouflaged as the body’s own defense system. Leukosomes were able to target inflamed tissues because they retained the same surface properties of the immune cell membranes from which they are made.

In the current study, the investigators studied leukosomes' nanoparticle protein corona in vivo. They described in the March 6, 2017, online edition of the journal ACS Nano a time-dependent quantitative and qualitative analysis of the protein corona adsorbed in vivo on leukosomes and control liposomes. They observed that leukosomes absorbed fewer proteins than liposomes and identified a group of proteins specifically adsorbed on leukosomes. It was felt that the presence of macrophage receptors on leukosomes’ surface neutralized their protein corona-meditated uptake by immune cells.

“Now we have a clearer understanding of how to use our leukosomes to evade those immune cells and prevent the body’s inflammatory response,” said senior author Dr. Ennio Tasciotti, director of the center for biomimetic medicine at Houston Methodist Hospital. “We have known overactive immune cells can behave like Pac Men, gobbling up the nanoparticles and ridding the body of these "foreign invaders" before they reach the intended target.”

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Gold Member
Collection and Transport System
PurSafe Plus®

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more